GMP Compliance for OTC, Dietary Supplement, and Cosmetic Manufacturers: What Is Different and What Is the Same
Most GMP consulting firms are built around pharma. This guide speaks directly to the manufacturers who are not.
GMP Compliance Beyond Traditional Pharma
When people hear GMP compliance, they often think of pharmaceutical manufacturing. However, OTC drug manufacturers, dietary supplement companies, and cosmetic brands face their own complex regulatory requirements and quality expectations. While the regulations differ, the need for a robust and defensible quality system remains the same.
Most GMP consulting firms are built around pharmaceutical products, biologics, and medical devices. As a result, OTC manufacturers, dietary supplement companies, and cosmetic brands often find themselves working with consultants who do not fully understand their specific regulatory environment or attempting to navigate compliance challenges without the specialized support they need.
Understanding where the regulations differ and where the expectations remain consistent is essential for building a quality system that can withstand regulatory scrutiny and support long-term growth.
How FDA GMP Expectations Differ Across Categories
OTC drug products manufactured in the United States are subject to 21 CFR Part 211, the same Current Good Manufacturing Practice regulations that govern finished pharmaceutical products. Requirements related to process validation, laboratory controls, batch record documentation, investigations, and deviation management are substantive and actively enforced. OTC drug manufacturing is generally subject to the same GMP requirements under 21 CFR Part 211 as other finished pharmaceutical products.
Dietary supplements operate under 21 CFR Part 111, which establishes manufacturing requirements specific to the supplement industry. Part 111 includes requirements for identity testing, component and product specifications, batch production records, complaint handling, and quality control operations. While the framework differs from Part 211 in several important ways, the expectation of a functioning and documented quality system remains the same.
Cosmetics have historically operated under a lighter regulatory framework, but that changed significantly with the passage of the Modernization of Cosmetics Regulation Act (MoCRA) in 2022. MoCRA expanded FDA oversight of cosmetic manufacturing and introduced new regulatory obligations for the industry.
Why This Matters
While FDA oversight differs across OTC drugs, dietary supplements, and cosmetics, regulatory expectations continue to evolve across all three categories. Organizations that proactively build strong quality systems are generally better positioned to avoid compliance observations, respond effectively to inspections, and scale operations as their business grows.
Companies that wait until they receive regulatory attention often find that the cost and effort required to remediate deficiencies significantly exceeds the investment required to establish a compliant quality system from the beginning.
MoCRA and What It Means for Cosmetic Manufacturers
MoCRA introduced facility registration requirements, mandatory serious adverse event reporting, product listing obligations, and for the first time, explicit GMP requirements for cosmetic manufacturers.
FDA is currently developing cosmetic GMP regulations through the rulemaking process, and cosmetic manufacturers should be building their quality infrastructure now rather than waiting for final regulations to be issued.
The organizations that will be best positioned when FDA finalizes its cosmetic GMP framework are those that have already implemented the foundational elements of a quality system, including documented manufacturing procedures, raw material controls, batch records, complaint management processes, and appropriate quality oversight.
Common Compliance Gaps in Non-Pharma GMP Environments
The compliance gaps we see most frequently in OTC, dietary supplement, and cosmetic operations tend to follow predictable patterns.
Incomplete Identity and Specification Testing. Part 111 requires identity testing on every lot of every dietary ingredient received. This requirement is often underestimated in scope and under-resourced in practice. Inadequate testing programs can quickly become a significant compliance risk.
Weak Supplier Qualification Programs. Supplier qualification programs are often informal or poorly documented. Knowing your suppliers is not sufficient. FDA expects documented qualification activities, ongoing performance monitoring, and objective evidence that incoming materials consistently meet established specifications.
Incomplete Batch Records. Batch records should provide a complete and accurate history of how a product was manufactured. Records that are incomplete, inconsistent, or fail to reflect actual manufacturing activities create both compliance and product quality risks.
Complaint Handling That Does Not Drive Quality Improvement. Many organizations collect consumer complaints but fail to connect those complaints to a broader quality review process. Complaints should be evaluated as potential indicators of process, product, or supplier issues and incorporated into continuous improvement activities.
Informal or Nonexistent Change Control Processes. As organizations grow, equipment, suppliers, formulations, manufacturing processes, and procedures inevitably change. Without a documented process for evaluating, approving, and implementing changes, companies may unintentionally introduce quality, compliance, or operational risks that could have been prevented.
When a Non-Pharma Manufacturer May Benefit from GMP Consulting Support
Not every dietary supplement company or cosmetic brand requires ongoing consulting support. However, there are situations where experienced external expertise can provide significant value.
Organizations building a quality system for the first time often benefit from establishing the right foundation from the beginning. The cost of correcting a poorly designed quality system can be substantially higher than investing in experienced guidance during implementation.
Similarly, companies responding to FDA observations, warning letters, or preparing for regulatory inspections often benefit from external support when their compliance posture is uncertain.
As organizations scale operations, add contract manufacturing partners, expand into new product categories, or enter new markets, the complexity of their compliance programs increases. Quality infrastructure must evolve alongside business growth to remain effective and sustainable.
Building a Compliance Program That Works Across Multiple Categories
For organizations that operate across product categories, one of the greatest challenges is creating a quality system that satisfies multiple regulatory frameworks without becoming fragmented or difficult to manage.
In many cases, the most effective approach is a unified quality system architecture supported by category-specific procedures where regulatory requirements diverge. Core quality system elements such as document control, deviation management, CAPA, supplier qualification, training, and change control can often be standardized across the organization while allowing for targeted procedural differences where required.
This approach is typically more sustainable, easier to audit, simpler to maintain, and better positioned to accommodate future regulatory changes.
Looking Ahead
Regulatory expectations for OTC drug, dietary supplement, and cosmetic manufacturers will continue to evolve, particularly as FDA advances implementation of MoCRA and expands oversight of cosmetic manufacturing.
Organizations that invest in scalable, risk-based quality systems today will be better positioned to adapt to future requirements, support sustainable growth, and maintain confidence in their compliance programs.
Connect with Pioneer GMP Consulting
Pioneer GMP Consulting works with OTC, dietary supplement, cosmetic, and GMP regulated manufacturers to build compliance programs that are practical, defensible, and aligned with the regulatory environments in which they operate. Whether your organization is establishing a quality system, preparing for regulatory inspection, responding to compliance concerns, or scaling operations, our team can help assess where your program stands and identify practical paths forward.
